How Does Semaglutide Work: The GLP-1 Class Explained

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The question "how does semaglutide work" is really a question about an entire hormone pathway. Semaglutide is one member of a class built to imitate and extend a signal your gut already sends after meals. This PlexusDx Education Hub explainer starts with that native signal, then builds up to the medications and the safety profile that share it. For foundational context, see what GLP-1 is.

The hormone at the center: GLP-1

Glucagon-like peptide-1 is an incretin hormone released by enteroendocrine L-cells in the small intestine in response to food. It prompts glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, slows gastric emptying, and signals satiety in the hypothalamus. Native GLP-1 lasts only minutes because the enzyme DPP-4 degrades it rapidly in circulation.

Turning minutes into days

Receptor agonists are engineered peptides, or in emerging cases small molecules, that engage the GLP-1 receptor while resisting DPP-4 degradation. That resistance stretches the half-life from minutes to hours or days, delivering the same physiological effects at a pharmacological level: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and reduced appetite through central satiety signaling. GIP/GLP-1 dual agonists such as tirzepatide add a second incretin mechanism at the GIP receptor.

Which medications belong to the class

FDA-approved GLP-1 receptor agonists as of April 2026 include exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), lixisenatide (historically, now discontinued in the U.S.), and semaglutide (Ozempic, Wegovy, Rybelsus). The GIP/GLP-1 dual agonist is tirzepatide (Mounjaro, Zepbound). The investigational triple agonist retatrutide, which targets GLP-1, GIP, and glucagon, has Phase 3 data but is not FDA-approved and is not sold by PlexusDx. Emerging oral non-peptide agonists such as orforglipron are in late-stage development.

Approved indications across the class

Indications vary by compound and product: type 2 diabetes for most products, chronic weight management for Wegovy, Saxenda, and Zepbound, cardiovascular risk reduction in type 2 diabetes for Ozempic, Trulicity, Victoza, and Rybelsus, and obstructive sleep apnea in adults with obesity for Zepbound as of December 2024. Pediatric indications exist for certain products. FDA labeling governs what is prescribed for which indication. Compare products in Ozempic versus Wegovy and Ozempic versus Mounjaro.

The safety profile they share

All FDA-approved GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies. Contraindications include a personal or family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2. The most common side effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation, and are typically most pronounced during dose escalation. Reported serious events include pancreatitis, gallbladder events, and acute kidney injury in the context of dehydration.

The variables upstream of the pathway

Even a well-understood mechanism meets individual biology. Variants in FTO, GLP1R, MC4R, and TCF7L2 shape baseline GLP-1 activity, appetite regulation, and energy-balance biology. The PlexusDx Precision Peptide Genetic Test maps 14 pathways, 49 peptides, 150+ genetic insights to bring that pathway-level context forward. It reads traits and never predicts response to a specific medication. Explore compounded 503A protocols in the Weight Management Protocols.

Why the mechanism matters in practice

Understanding the pathway is not just academic. It explains several things patients notice, from why the schedule ramps slowly to why these medications behave differently from older approaches.

Why effects build gradually

Because the class acts on gastric emptying, satiety signaling, and glucose-dependent insulin secretion, the body adjusts to those effects over time. That is one reason labeling calls for a starting dose that increases in steps: a gradual ramp gives the gastrointestinal system time to adapt, which is why the most pronounced side effects tend to cluster during escalation rather than at steady state.

How the class works with the body's own signal

Rather than forcing an unrelated effect, receptor agonists amplify a signal your gut already produces after meals. The glucose-dependent nature of the insulin response is central here: insulin secretion is prompted in the context of elevated glucose, which is part of why the mechanism differs from approaches that push insulin regardless of glucose. Understanding that distinction helps frame a more informed conversation with a healthcare provider.

Where the pathway meets the individual

The mechanism is shared across the class, but how any one person experiences it is shaped by their own physiology and medical history. That is why labeling emphasizes provider supervision and gradual dosing rather than a one-size-fits-all schedule. Understanding the pathway gives you the vocabulary to ask better questions, but the specifics of any regimen belong in a conversation with a qualified healthcare provider.

Frequently Asked Questions

Why does semaglutide last so much longer than natural GLP-1?

Native GLP-1 survives only minutes because the enzyme DPP-4 degrades it quickly. Semaglutide is engineered to resist that degradation while still engaging the GLP-1 receptor, extending its action from minutes to a far longer window. That durability lets it deliver the hormone's physiological effects at a pharmacological level.

Is tirzepatide the same class as semaglutide?

They overlap but differ. Semaglutide is a GLP-1 receptor agonist, while tirzepatide is a GIP/GLP-1 dual agonist that engages both the GLP-1 receptor and the GIP receptor, adding a second incretin mechanism. Both act on insulin secretion, glucagon, gastric emptying, and satiety, but through partly different receptor targets.

What safety warning applies to the whole class?

Every FDA-approved GLP-1 receptor agonist and GIP/GLP-1 dual agonist carries a class boxed warning for thyroid C-cell tumor risk seen in rodent studies, with contraindications for personal or family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2. Discuss your full history with a healthcare provider.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.